SerpApi.Org
Residents and doctors in the Pacific Northwest now face a diagnosis they were never trained to expect. Valley fever, a fungal lung infection caused by Coccidioides spores inhaled from contaminated soil, has been confirmed through soil sampling and genomic case matching in Washington and Oregon, well north of the Arizona and California deserts where the disease has historically concentrated. The CDC added Washington to its list of states with documented local Valley fever transmission in 2013, and Oregon’s health authority has classified the disease as an emerging infection in the region. For people living in these states, the practical risk is straightforward: a respiratory illness that local clinicians may not think to test for, leading to delayed or missed diagnoses.
Why confirmed soil colonization in Washington changes the diagnosis picture
Valley fever is not simply showing up in travel-related cases far from the desert. The fungus itself, Coccidioides immitis, has been recovered directly from Washington soil and linked to a local human infection through genomic comparison. A peer-reviewed study published in Clinical Infectious Diseases used single-nucleotide polymorphism analysis to match environmental isolates from Washington soil with a patient’s clinical isolate, confirming that the infection was acquired locally rather than during travel. That finding shifted the disease from a theoretical concern to a documented local threat.
The CDC’s national surveillance summary for coccidioidomycosis, histoplasmosis, and blastomycosis reinforced this shift, stating that while the disease is most common in the Southwest, it is also acquired as far north as Washington. Oregon’s health authority separately describes Valley fever as an emerging infection in Oregon and the greater Pacific Northwest, monitored through its Emerging Infections Program. These are not speculative projections. They reflect confirmed detections and active state-level tracking.
The question of why Coccidioides is surviving in Pacific Northwest soils connects to a testable hypothesis: longer dry seasons combined with episodic heavy rain may be expanding viable fungal habitat northward. In arid and semi-arid zones, Coccidioides thrives in alkaline, undisturbed soil during dry periods, then releases spores when wind or disturbance follows rain. If warming temperatures are extending dry windows in parts of central Washington and Oregon while periodic storms still deliver moisture, the fungal life cycle could establish in soils that were previously too cool or too consistently wet. Testing this would require correlating multi-year soil qPCR positivity rates at known colonization sites with local weather station records and incident case clusters. That work has not been published to date, but the environmental conditions are consistent with the pattern.
Soil sampling, genomic sequencing, and the evidence trail from 2013 to 2016
The evidence for local Valley fever acquisition in the Pacific Northwest rests on a sequence of soil and clinical investigations. In 2013, Coccidioides immitis was detected in Washington soil and successfully cultured, marking the first confirmed environmental isolation of the fungus outside its historically recognized range. That same year, the CDC added Washington to its geographic distribution list for local Valley fever spread. Washington’s Department of Health now reports locally acquired coccidioidomycosis cases and soil detections organized by county, treating the disease as a notifiable condition requiring clinical reporting.
Subsequent investigations deepened the evidence. A study published in Emerging Infectious Diseases applied whole-genome sequencing to Washington case isolates to determine which infections were likely locally acquired versus imported from travel to the Southwest. Researchers at the CDC used this genomic approach to distinguish Washington-specific strains, supporting the conclusion that the state harbors an ongoing, if small, endemic focus. Separately, soil sampling conducted at a known Washington colonization site in 2016 used qPCR, culture, whole-genome sequencing, and soil chemistry analysis to characterize the environmental factors that allow C. immitis to persist, with results published in Applied and Environmental Microbiology.
Oregon’s evidence base is thinner but still concrete. Enhanced surveillance across 14 states in 2016 identified soil DNA detection of Coccidioides in central Oregon and documented a culture-confirmed coccidioidomycosis case in the state in a patient without recent travel to known endemic areas. That finding, reported in Emerging Infectious Diseases, placed Oregon alongside Washington as a state where local acquisition is plausible and where clinicians should consider the diagnosis even without a Southwest travel history. The CDC’s own overview of endemic areas now acknowledges that Valley fever can occur outside the traditional desert Southwest, underscoring the need for awareness in newly affected regions.
Gaps in surveillance and what Pacific Northwest residents should watch for
Several questions remain open. The most recent national surveillance data covering coccidioidomycosis across states was published using 2019 case reports. No updated county-level incidence counts or hospitalization figures for Washington or Oregon after that surveillance year are publicly available. The 2016 Washington soil study confirmed ongoing colonization at a specific site, but no subsequent published environmental sampling has established whether the fungus has spread to additional locations or whether its presence is stable, expanding, or contracting.
Travel-history verification for Oregon cases also has limits. The 2016 enhanced surveillance report identified a culture-confirmed Oregon case without recent travel to known endemic areas, but detailed public release of how travel histories were verified for all suspected cases has not been provided. That leaves some uncertainty about how many cases may truly be locally acquired. Under-ascertainment is likely, because mild Valley fever can resemble a routine viral respiratory infection and resolve without specific treatment, never reaching a mycology laboratory or triggering confirmatory testing.
For residents of Washington and Oregon, the practical guidance is less about panic and more about pattern recognition. Valley fever often begins with fever, cough, fatigue, chest pain, and sometimes rash, typically appearing one to three weeks after exposure to dusty outdoor conditions. People who work or recreate in dry, disturbed soil-such as construction workers, agricultural laborers, off-road vehicle users, and dog owners on dusty trails-may face higher exposure risk if they are in areas where Coccidioides has been detected or is suspected. Anyone who develops a persistent pneumonia-like illness after such exposures should mention Valley fever to their clinician, especially if routine antibiotics fail to help.
Clinicians, in turn, can adapt by updating their mental maps of where Valley fever is possible. In both Washington and Oregon, that means asking about in-state travel to dry inland regions, not just trips to Arizona or California. When imaging shows pneumonia that is slow to resolve, or when patients have prolonged cough and fatigue without a clear bacterial cause, ordering serologic tests for Coccidioides and considering fungal cultures or molecular assays can shorten the time to diagnosis. Public health agencies can support this by providing updated county-level risk maps and clear testing algorithms tailored to local practice.
Because Valley fever is not transmitted person-to-person, community-level prevention hinges on exposure reduction and early detection rather than isolation. Simple measures such as wetting soil before digging, using N95 respirators during high-dust construction activities, and closing windows during dust storms can reduce inhalation of spores in areas where the fungus is present. For immunocompromised individuals and pregnant people-groups at higher risk for severe disease-avoiding unnecessary dusty outdoor activities in known or suspected exposure zones is a reasonable precaution.
The Pacific Northwest’s experience with Valley fever is still in its early chapters. Confirmed soil colonization in Washington, suggestive environmental detections in Oregon, and a growing list of locally acquired cases collectively show that the historical map of this disease no longer stops at the California border. Yet the region lacks up-to-date environmental surveys, fine-grained incidence data, and robust clinician awareness. Addressing those gaps will determine whether Valley fever remains a rare, occasionally missed diagnosis or becomes a recognized part of the respiratory disease landscape in Washington and Oregon. For now, the message to residents and providers is the same: in the right clinical and environmental context, Valley fever belongs on the differential-even under gray Northwestern skies.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
